Related Experiment Videos
[Molecular therapy in lung cancer]
1Institut für Medizinische Onkologie, Inselspital, Bern. oliver.gautschi@insel.ch
Therapeutische Umschau. Revue Therapeutique
|July 16, 2004
Summary
New lung cancer therapies target tumor growth and spread. This review highlights advanced compounds like receptor inhibitors and gene therapy for incurable lung cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Context:
- Lung cancer is a leading cause of cancer death in Europe, with over 370,000 new cases annually.
- Approximately 70% of patients present with advanced disease, rendering curative treatment impossible.
- Current chemotherapy offers limited survival benefits for advanced lung cancer.
Purpose:
- To review novel anti-cancer agents targeting specific molecules crucial for tumor progression.
- To focus on compounds in late-stage clinical development for lung cancer treatment.
Summary:
- The review covers emerging therapies including epidermal growth factor receptor inhibitors, receptor tyrosine kinase inhibitors, and anti-angiogenic agents.
- It also discusses matrix metalloproteinase inhibitors, gene therapy, and antisense therapy as potential lung cancer treatments.
- These targeted agents represent a new class of anti-cancer drugs aimed at inhibiting tumor growth and metastasis.
Impact:
- These advancements offer new hope for patients with advanced, incurable lung cancer.
- Targeted therapies may improve survival and quality of life for lung cancer patients.
- The development of these novel agents signifies a paradigm shift in lung cancer treatment strategies.